PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Almac Group Surpasses £1 Billion Revenue with Latest Annual Accounts Reporting Record Revenues, Profit and Employee Numbers

Almac Group, the global contract pharmaceutical development and manufacturing organisation, has today announced its highest ever revenue, profit and employee numbers. 

Figures released for Almac’s financial year ending 30 September 2024 reported £1.027 billion of revenues, a £69.5 million (7%) increase from 2023.  Pre-tax profits rose by 27% to £119 million, up from £93.8 million in the previous year, and average employee numbers grew by 3% over the same period.

Almac reinvests all profit back into the business and these financial results mark the fourth year of Almac Group’s £400 million+ global capital investment programme, announced in November 2021.  This programme has included the development of a Centre of Excellence for Diagnostic development and commercial manufacturing, a state of the art 100,000 sq ft pharmaceutical manufacturing facility, and an expansion of cryogenic and ultra-low temperature service capabilities for clinical supply across Durham, North Carolina and Singapore.  A major expansion continues to clinical production and distribution capabilities in Souderton, Pennsylvania.

Almac, which currently employs more than 7,700 people worldwide, is at the forefront of developing, manufacturing, testing and distributing essential medicines to patients around the world. During this financial year the group was involved in the development of hundreds of life-saving drugs spanning more than 20 therapeutic areas including oncology, cardiology, immunology, gene therapy and neurology.

Alan Armstrong, Almac Group Chairman and CEO said: “Today’s results mark another successful year of growth for Almac.  As a privately-owned and independent company, we re-invest all our profits back into the business, enabling us to innovate and expand to meet the growing needs of our global clients, working in partnership to advance human health.

“I am proud of the continued progress we are making, which is thanks to the dedication of our valued global workforce.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026